Teva
Teva 'disappointed' by Irish consultants' boycott of its pharmaceuticals, company tells 'Post'
Teva told the Post it remains committed to working constructively with healthcare professionals across Ireland and to supporting patients through the "consistent supply of high-quality medicines."
The curse of being Israel's most valuable company
Mega deal: Teva acquires Emalex for approximately $900 million
IATI CEOs Forum meets in Kiryat Gat to discuss multinational industry resilience
Teva hopes generic EpiPen will sell well in U.S. market
An EpiPen, or epinephrine auto-injector, is a medication used to treat serious allergic reactions in emergencies.
U.S. settles with Teva over keeping generic drugs off market
The agency has said that the deals cost consumers billions annually in higher drug costs.
Teva CEO: Tough year ahead, but we're hitting cost-cutting targets
The successful Israeli-based generic medication manufacturer has been forced to downsize, but emphasized there will be no second round of restructuring or new site closures.
Israeli scientists abroad: We want to come home
At a workshop in Tel Aviv, the country’s brightest face a hard choice. Can they bring home the skills they have acquired?
Israeli drug giant Teva to move offices to Tel Aviv
"The expected move-in date will be mid-2020," Teva SVP global human resources Mark Sabag told Globes.
Israeli drug-maker Teva to recall certain blood pressure medicine in U.S.
Teva has not received any reports of adverse events signaling a potential link or exposure to valsartan, the health regulator said.
Teva continues to wobble as rival drug receives FDA approval
Only two weeks ago, Teva received approval for its newly-developed migraine drug known as Ajovy, raising hopes of improved financial fortunes.
U.S. approval of Teva drug could help reverse company’s migraines
The newly-approved preventive migraine drug could bring in as much as $500 million in sales annually.
Will migraine drug approval make Teva a success again?
The U.S. Food and Drug Administration approved a new migraine treatment Teva created, which has potentially 39 million Americans buyers.